About this Research Topic
Recent advancements in the treatment landscape for relapsed and refractory multiple myeloma have introduced BCMA (B-cell maturation antigen) therapies, a promising addition to the therapeutic arsenal. However, these innovative treatments are accompanied by unique side effects, including cytokine release syndrome, neurotoxicity, infections, prolonged cytopenia, and immunodeficiency. The novelty of these therapies has resulted in a need for more comprehensive data regarding the therapies' efficacy and potential, as well as the incidence/outcomes of associated complications and side effects.
We invite researchers, clinicians, and experts in the field to contribute to this research topic, fostering a comprehensive understanding of the therapeutic potential of anti-BCMA treatment in myeloma and the treatment's associated complications. The gathered insights will contribute significantly to optimizing patient care and guiding future developments in the field.
This topic is particularly interested in covering:
-- Incidence of various types of side effects in patients treated with anti-BCMA therapy in myeloma.
-- Survival outcomes in the myeloma patients treated with anti-BCMA therapy.
-- Predictive modelling of incidence of anti-BCMA treatment-associated complications.
-- Preventative and treatment strategies and their outcomes to treat these complications.
We welcome manuscripts considering real-world data, pooled analyses, and diverse research studies addressing the outcomes and/or complications associated with anti-BCMA therapy in multiple myeloma. This includes but is not limited to original research, reviews (systematic and mini reviews), cohort studies, clinical trials, case reports, and brief research reports.
We invite researchers, clinicians, and experts in the field to contribute to this research topic, fostering a comprehensive understanding of the therapeutic potential of anti-BCMA treatment in myeloma and the treatment's associated complications. The gathered insights will contribute significantly to optimizing patient care and guiding future developments in the field.
This topic is particularly interested in covering:
-- Incidence of various types of side effects in patients treated with anti-BCMA therapy in myeloma.
-- Survival outcomes in the myeloma patients treated with anti-BCMA therapy.
-- Predictive modelling of incidence of anti-BCMA treatment-associated complications.
-- Preventative and treatment strategies and their outcomes to treat these complications.
We welcome manuscripts considering real-world data, pooled analyses, and diverse research studies addressing the outcomes and/or complications associated with anti-BCMA therapy in multiple myeloma. This includes but is not limited to original research, reviews (systematic and mini reviews), cohort studies, clinical trials, case reports, and brief research reports.
Keywords: multiple myeloma, CAR-T Therapy, Bispecific Antibodies, B-cell Maturation Antigen (BCMA), Monoclonal Antibodies, Relapsed/Refractory Myeloma
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
